Alessa Therapeutics, a privately held drug development company developing an innovative and proprietary localized drug delivery technology for the treatment of prostate disease, announced the enrollment of the first patient in the company’s Enolen® clinical study at the National Cancer Institute (NCI), part of the National Institutes of Health.
Pamela Munster is the lead UCSF inventor.